top of page
Our Pipeline
Dragonfly’s novel Cytokine and TriNKET® immune engagers harness NK cells, CD8+ T cells and other immune effectors to potently kill diseased targets to treat autoimmune and inflammatory diseases, cancers, neurological disorders and other diseases with a uniquely favorable safety profile.
Dragonfly’s clinical development
pipeline is robust and continues to grow
Oncology
Autoimmune
Approved
Target
Preclinical
Phase 1
Phase 2
Phase 3
Product Candidate
Indications
DF5112
Undisclosed
Autoimmune Disease
Multiple
Undisclosed
Autoimmune and Fibrotic Disorders
bottom of page